Evaluation of the Angiogenic Properties of Brugia malayi Asparaginyl-tRNA Synthetase and its Mutants: A Study on the Molecular Target for Antifilarial Drug Development

Author(s):  
Rithika Chandrasekar ◽  
Sanjana Sivanesan ◽  
Mahalakshmi Natarajan ◽  
K. Naveena ◽  
N Preetha ◽  
...  
2019 ◽  
Vol 14 (12) ◽  
pp. 2663-2671 ◽  
Author(s):  
Thomas A. Scott ◽  
Sibyl F. D. Batey ◽  
Patrick Wiencek ◽  
Govind Chandra ◽  
Silke Alt ◽  
...  

2015 ◽  
Vol 68 (8) ◽  
pp. 540-542 ◽  
Author(s):  
Mostafa E Rateb ◽  
Dong Yang ◽  
Sanja Vodanovic-Jankovic ◽  
Zhiguo Yu ◽  
Michael A Kron ◽  
...  

2003 ◽  
Vol 129 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Michael Kron ◽  
Michael Petridis ◽  
Youli Milev ◽  
Joseph Leykam ◽  
Michael Härtlein

2013 ◽  
Vol 69 (5) ◽  
pp. 785-795 ◽  
Author(s):  
Sameena Khan ◽  
Ankur Garg ◽  
Noelia Camacho ◽  
Jason Van Rooyen ◽  
Anil Kumar Pole ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0146132 ◽  
Author(s):  
Jeeva Jothi D ◽  
Muthu Dhanraj ◽  
Shanmugam Solaiappan ◽  
Sanjana Sivanesan ◽  
Michael Kron ◽  
...  

2009 ◽  
Vol 23 (S1) ◽  
Author(s):  
Amanda Arnold ◽  
Amanda Schulman ◽  
Charles Bach ◽  
Sam Bach ◽  
Andy Faught ◽  
...  

2006 ◽  
Vol 8 (1) ◽  
pp. 109-113 ◽  

The US National Institute of Mental Health supported an initiative to facilitate the development of pharmacological agents for enhancing neurocognition in patients with schizophrenia. This has been accomplished through a consensus-building process that has included representatives from academia, the pharmaceutical industry, and government. The group has addressed obstacles to drug development that include (i) the lack of a well-accepted instrument for measuring neurocognition in clinical trials; (ii) the lack of a consensus on the best molecular target or targets for drug development; (iii) the lack of a consensus regarding the optimal trial design for either comedication that improves cognition when added to an antipsychotic or a broad spectrum agent that improves cognition and treats psychosis; and (iv) the approaches of regulatory agencies such as the US Food and Drug Administration to approving and labeling a new agent.


2019 ◽  
Author(s):  
Thomas A. Scott ◽  
Sibyl F. Batey ◽  
Patrick Wiencek ◽  
Govind Chandra ◽  
Silke Alt ◽  
...  

AbstractTo meet the ever-growing demand of antibiotic discovery, new chemical matter and antibiotic targets are urgently needed. Many potent natural product antibiotics which were previously discarded can also provide lead molecules and drug targets. One such example is the structurally unique β-lactone obafluorin, produced by Pseudomonas fluorescens ATCC 39502. Obafluorin is active against both Grampositive and -negative pathogens, however the biological target was unknown. We now report that obafluorin targets threonyl-tRNA-synthetase and we identify a homologue, ObaO, which confers self-immunity to the obafluorin producer. Disruption of obaO in P. fluorescens ATCC 39502 results in obafluorin sensitivity, whereas expression in sensitive E. coli strains confers resistance. Enzyme assays demonstrate that E. coli threonyl-tRNA synthetase is fully inhibited by obafluorin, whereas ObaO is only partly susceptible, exhibiting a very unusual partial inhibition mechanism. Altogether, our data highlight the utility of a self-immunity guided approach for the identification of an antibiotic target de novo and will ultimately enable the generation of improved obafluorin variants.


PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0171402
Author(s):  
Jeeva Jothi D ◽  
Muthu Dhanraj ◽  
Shanmugam Solaiappan ◽  
Sanjana Sivanesan ◽  
Michael Kron ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document